News and Events NovaBiotics Announces First Patient Enrolment into the Cysteamine Domain of REMAP-CAP Dec 8, 2021 NovaBiotics to Present New Data at Upcoming North American Cystic Fibrosis Conference Nov 1, 2021 NovaBiotics to Present Preclinical Data on NP339 and Sponsor Symposium on New Antifungals at Upcoming 10th Congress on Trends in Medical Mycology Oct 5, 2021 NovaBiotics publishes further data on the mechanism of action of its candidate NM001 therapy for cystic fibrosis (CF) Sep 23, 2021 NovaBiotics Highlights Advantages of Novel Immune-Based Approach to Combatting Fungal and Bacterial Infectious Diseases at Peptide Therapeutics Forum 2021 Aug 25, 2021 NovaBiotics Announces Presentation at Upcoming Peptide Therapeutics Forum 2021 Aug 2, 2021 NovaBiotics Named as One of Scotland’s Top Ten Biotech Companies to Watch Out For Jul 7, 2021 NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia Jun 21, 2021 NovaBiotics Announces Publication of Data Elucidating NP339’s Broad Antifungal Activity in Antimicrobial Agents and Chemotherapy Jun 1, 2021 NovaBiotics attending the BIO Digital Meeting, June 2021 May 21, 2021 « Older Entries Next Entries » Categories Press Releases Events In the news Archives 2021 2020 2019
NovaBiotics to Present Preclinical Data on NP339 and Sponsor Symposium on New Antifungals at Upcoming 10th Congress on Trends in Medical Mycology Oct 5, 2021
NovaBiotics publishes further data on the mechanism of action of its candidate NM001 therapy for cystic fibrosis (CF) Sep 23, 2021
NovaBiotics Highlights Advantages of Novel Immune-Based Approach to Combatting Fungal and Bacterial Infectious Diseases at Peptide Therapeutics Forum 2021 Aug 25, 2021
NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia Jun 21, 2021
NovaBiotics Announces Publication of Data Elucidating NP339’s Broad Antifungal Activity in Antimicrobial Agents and Chemotherapy Jun 1, 2021